TY - JOUR T1 - Bi-weekly Capecitabine–Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer –The PHOENiX Trial JF - Anticancer Research JO - Anticancer Res SP - 3437 LP - 3443 VL - 36 IS - 7 AU - TAKANORI MATSUI AU - NAOKI NAGATA AU - KEIJI HIRATA AU - SATOSHI OKAZAKI AU - SUMITO SATO AU - MASATO NAKAMURA AU - HOMIN KIM AU - KOJI OBA AU - JUNICHI SAKAMOTO AU - HIDEYUKI MISHIMA Y1 - 2016/07/01 UR - http://ar.iiarjournals.org/content/36/7/3437.abstract N2 - Aim: This phase II study assessed the efficacy and toxicity of an intermittent weekly capecitabine regimen in combination with oxaliplatin (XELOX) plus bevacizumab as a first-line treatment of metastatic colorectal cancer (mCRC). Patients and Methods: Patients with measurable mCRC who were to receive first-line chemotherapy were enrolled onto this disease-oriented multicenter phase II trial. Patients with mCRC were required to have Eastern Cooperative Oncology Group performance status of 0 to 1, to be aged >20 years, and to have adequate organ function. Localization of tumor, toxicities, response rate, progression-free survival (PFS) and time to progression (TTP) were studied. Capecitabine dose was 2,500 mg/m2/day on days 1-7 (n=47) and was increased to 3,000 mg/m2/day (n=5) in combination with oxaliplatin (85 mg/m2) and bevacizumab (5 mg/kg), repeated every 2 weeks. Results: A total of 51 patients were enrolled from 14 institutions from December 2011 to July 2012. The median age was 66 (range=38-85) years, 29 (56.9%) had colonic cancer and 22 (43.1%) had rectal cancer in this study. Pertinent grade 3/4 toxicities were neutropenia (13.7%), peripheral neuropathy (13.7%), hypertension (13.7%), gastrointestinal perforation (3.9%), and hand-foot syndrome (5.9%). The response rate was 51% (one complete and 25 partial responses). Median PFS and TTP were 344 days and 196 days, respectively. Median overall survival has not been reached yet. Conclusion: The first-line treatment of mCRC using a biweekly combination of XELOX plus bevacizumab can also be administered safely and effectively in Japan. It is suggested that this regimen is an appropriate option for the treatment of mCRC. ER -